DHR-N 2.34 GE-N 4.09 AMZN-Q -0.22 SES-T 0.48 UBER-N 3.39 BN-T 1.72 HPS.A-T 1.34
ID Biomedical (IDB-T)

ID Biomedical (IDB-T)

0 watching

0.00
0.00 (0.00%) 1d
0

Related posts

Nervous markets await Nvidia
HOLD

ID Biomedical(IDB-T)

Sep 20, 2005
GlaxcoSmithKline (GSK-N) is taking the company over. Speculation is that someone else will come in with a better offer. Can't see much risk in holding on to your shares.
Norman LevineNorman Levine
Unknown
Unlock Rating
$34.900

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ID Biomedical(IDB-T)

May 09, 2005
Have a large vaccine contract in the US. Should have a large increase in earnings and the stock should have a lot of upside.
Jean-Francois TardifJean-Francois Tardif
Owned
Unlock Rating
$21.500

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ID Biomedical(IDB-T)

Dec 03, 2004
Biotech stocks are very risky. This one has done very well on the flu vaccine problem in the US. A low margin business. Very expensive.
Jean-Francois TardifJean-Francois Tardif
No
Unlock Rating
$20.050

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ID Biomedical(IDB-T)

Aug 23, 2004
The pharmaceutical sector has been torn apart. This company that has done a very good job in managing and developing some products.
Robert FloydRobert Floyd
Owned
Unlock Rating
$14.640

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

ID Biomedical(IDB-T)

Sep 22, 2003
Likes the story. Has had a pretty good run, but has more room to go. Very strong news out of the company. Some trial results still to come out in the next little while.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$25.470

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

ID Biomedical(IDB-T)

Jul 29, 2003
Developing a flu vaccine. Well cashed up. Would buy it, but at a lower level.
Peter HodsonPeter Hodson
No
Unlock Rating
$17.540

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ID Biomedical(IDB-T)

Mar 03, 2003
Good product. In final phases of testing.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$8.160

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

ID Biomedical(IDB-T)

Feb 04, 2003
Very volatile. Well managed and has a lot of cash.
Peter HodsonPeter Hodson
Unknown
Unlock Rating
$10.060

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ID Biomedical(IDB-T)

Jan 15, 2003
Still has substantial upside. Into some interesting products.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$11.450

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

ID Biomedical(IDB-T)

Apr 05, 2002
(Was a top pick on Dec 21 up 50%) Can still go higher.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$9.610

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ID Biomedical(IDB-T)

Dec 21, 2001
Well capitalized. Strong management.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$6.640

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ID Biomedical(IDB-T)

Jul 09, 2001
Robert FloydRobert Floyd
Unknown
Unlock Rating
$5.150

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ID Biomedical(IDB-T)

Jun 14, 2001
Strong cash position. Good mngmnt. Good outlook.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$6.400

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ID Biomedical(IDB-T)

May 14, 2001
Well capitalized. Good product line.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$5.950

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ID Biomedical(IDB-T)

Mar 28, 2001
New acquisition is a good fit. Strong cash positions.
Robert FloydRobert Floyd
Unknown
Unlock Rating
$4.810

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 15 of 19 entries
Next PageNext Page

ID Biomedical(IDB-T) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for ID Biomedical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ID Biomedical(IDB-T) Frequently Asked Questions

What is ID Biomedical stock symbol?

ID Biomedical is a OTC stock, trading under the symbol IDB-T on the (). It is usually referred to as or IDB-T

Is ID Biomedical a buy or a sell?

In the last year, there was no coverage of ID Biomedical published on Stockchase.

Is ID Biomedical a good investment or a top pick?

ID Biomedical was recommended as a Top Pick by on . Read the latest stock experts ratings for ID Biomedical.

Why is ID Biomedical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ID Biomedical worth watching?

In the last year 0 stock analysts on Stockchase covered ID Biomedical. The stock is worth watching.

What is ID Biomedical stock price?

On , ID Biomedical (IDB-T) stock closed at a price of $.

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

CJT-T 0.41$84.44
META-Q 24.81$597.02
EXC-N -0.12$46.48
SHAK-N 5.66$94.37
ABT-N 1.94$132.82

Today's Top Picks

DHR-N 2.34$199.05
GE-N 4.09$207.7
AMZN-Q -0.22$189.98
SES-T 0.48$13.64
UBER-N 3.39$84.28

Popular Articles

Latest Sell Signals

BIP.UN… 1$42.71
HSBC-N 1.38$56.51
INTC-Q 0.64$20.62
T-T -0.38$20.72
AC-T 0.58$14.69

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Dan Rohinton

Dan Rohinton

iA Global Asset Management

Richard Fogler

Richard Fogler

Kingwest & Company

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

© Stockchase Inc.